These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22674145)

  • 21. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
    Markopoulos C
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):179-94. PubMed ID: 23406559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of molecular profiling for early breast cancer.
    Gauchan D; Ramaekers R; Copur SM
    J Clin Oncol; 2015 May; 33(14):1627. PubMed ID: 25847939
    [No Abstract]   [Full Text] [Related]  

  • 23. Early diffusion of gene expression profiling in breast cancer patients associated with areas of high income inequality.
    Ponce NA; Ko M; Liang SY; Armstrong J; Toscano M; Chanfreau-Coffinier C; Haas JS
    Health Aff (Millwood); 2015 Apr; 34(4):609-15. PubMed ID: 25847643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic profile of breast cancer.
    Plun-Favreau J; Svedman C; Valentine W; Rouzier R
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):393-4. PubMed ID: 25797274
    [No Abstract]   [Full Text] [Related]  

  • 25. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In response: Genomic profile of breast cancer.
    Seguí MA; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna S; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):395-7. PubMed ID: 25797142
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
    Lamond NW; Skedgel C; Rayson D; Lethbridge L; Younis T
    Breast Cancer Res Treat; 2012 Jun; 133(3):1115-23. PubMed ID: 22361999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
    Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
    Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of the 70-gene signature versus adjuvant! Online and systematic chemotherapy for risk stratification of patients with node-negative breast cancer: does accuracy matter?
    Rahilly-Tierney C; Walton SM
    J Clin Oncol; 2015 May; 33(14):1628-9. PubMed ID: 25847938
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
    Alvarado MD; Mohan AJ; Esserman LJ; Park CC; Harrison BL; Howe RJ; Thorsen C; Ozanne EM
    Ann Surg Oncol; 2013 Sep; 20(9):2873-80. PubMed ID: 23812769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
    Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
    Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.
    Thavorn K; Coyle D; Hoch JS; Vandermeer L; Mazzarello S; Wang Z; Dranitsaris G; Fergusson D; Clemons M
    Support Care Cancer; 2017 Aug; 25(8):2505-2513. PubMed ID: 28281050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
    Felts JL; Zhu J; Han B; Smith SJ; Truica CI
    Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis.
    Pandharipande PV; Harisinghani MG; Ozanne EM; Specht MC; Hur C; Lee JM; Gazelle GS
    AJR Am J Roentgenol; 2008 Nov; 191(5):1308-19. PubMed ID: 18941062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
    Ethier JL; Amir E
    Mol Diagn Ther; 2016 Aug; 20(4):307-13. PubMed ID: 27235162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients.
    Lee JH; Glick HA; Hayman JA; Solin LJ
    J Clin Oncol; 2002 Jun; 20(11):2713-25. PubMed ID: 12039934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.